Skip to content
10-Q

Quarterly Report

KALA BIO, Inc. KALA

0001104659-26-062397

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 14, 2026 18.59M sh
Shares Diluted Q1 2026 · Mar 31, 2026 11.87M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 126.92K sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$2.9M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$8.82M
Short Term Investments Q1 2026 · Mar 31, 2026 $7M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $1.76M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $7.56M
Stockholders Equity Q1 2026 · Mar 31, 2026 $10.76M
Stockholders Equity Q1 2026 · Dec 31, 2025 $7M
Stockholders Equity Q1 2026 · Mar 31, 2025 $5.71M
Stockholders Equity Q1 2026 · Dec 31, 2024 $12.33M
Current Liabilities Q1 2026 · Mar 31, 2026 $1.56M
Current Liabilities Q1 2026 · Dec 31, 2025 $2.49M
Total Liabilities Q1 2026 · Mar 31, 2026 $1.56M
Total Liabilities Q1 2026 · Dec 31, 2025 $2.49M
Current Assets Q1 2026 · Mar 31, 2026 $12.32M
Current Assets Q1 2026 · Dec 31, 2025 $9.49M
Total Assets Q1 2026 · Mar 31, 2026 $12.32M
Total Assets Q1 2026 · Dec 31, 2025 $9.49M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.14
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$70.49
Eps Basic Q1 2026 · Mar 31, 2026 −$0.14
Eps Basic restated Q1 2026 · Mar 31, 2025 −$70.49
Rd Expense Q1 2026 · Mar 31, 2026 $61K
Rd Expense Q1 2026 · Mar 31, 2025 $6.06M
Net Income Q1 2026 · Mar 31, 2026 −$1.62M
Net Income Q1 2026 · Mar 31, 2025 −$8.95M
Operating Income Q1 2026 · Mar 31, 2026 −$1.8M
Operating Income Q1 2026 · Mar 31, 2025 −$10.67M